Announcement on Approval by CDE for the Key Phase III Clinical Study of KC1036 as a Second-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma

About this update from Beijing Konruns Pharmaceutical Co., Ltd. Class A

Announcement on Approval by CDE for the Key Phase III Clinical Study of KC1036 as a Second-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Beijing Konruns Pharmaceutical Co., Ltd. Class A